Identification of Gangliosides and Ceramides As Biomarkers for Mucopolysaccharidosis Type II (hunter Syndrome) Through Untargeted Lipidomic Analysis

Overview

Journal Metabolomics

Publisher Springer

Specialty Endocrinology

Date 2025 Mar 2

PMID 40024935

Authors

Asma Farjallah

Bruno Maranda

Roberto Giugliani

Christiane Auray-Blais

Affiliations

Soon will be listed here.

Abstract

Introduction: Mucopolysaccharidosis type II (Hunter syndrome) is an X-linked recessive disorder caused by iduronate-2-sulfatase deficiency, affecting mainly male patients. The lack of its enzyme activity causes the accumulation of the glycosaminoglycans heparan sulfate and dermatan sulfate in all body tissues and leads to a secondary accumulation of gangliosides and ceramides.

Objective And Methods: We conducted a lipidomic study to investigate the dysregulation of lipid pathways in neuronopathic MPS type II. A modified liquid extraction was performed for untargeted lipid analysis. A reverse phase ultraperformance liquid chromatography coupled to quadrupole time-of-flight (UPLC-QTOF) mass spectrometry allowed the identification of upregulated ganglioside and ceramide biomarkers in the plasma and urine of a MPS II patient group compared to a healthy control group.

Results: The altered pathways, including those related to glycerophospholipid metabolism and fatty acid oxidation, highlight the essential role of lipid metabolism in the progression of the disease.

Conclusion: The accumulation of gangliosides and ceramides could be associated with the neuropathology in various lysosomal storage diseases including MPS II.

References

Auray-Blais C, Bherer P, Gagnon R, Young S, Zhang H, An Y . Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol Genet Metab. 2010; 102(1):49-56. DOI: 10.1016/j.ymgme.2010.09.003. View

Auray-Blais C, Lavoie P, Tomatsu S, Valayannopoulos V, Mitchell J, Raiman J . UPLC-MS/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses. Anal Chim Acta. 2016; 936:139-48. DOI: 10.1016/j.aca.2016.06.054. View

Ausseil J, Desmaris N, Bigou S, Attali R, Corbineau S, Vitry S . Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One. 2008; 3(5):e2296. PMC: 2396504. DOI: 10.1371/journal.pone.0002296. View

Bellettato C, Hubert L, Scarpa M, Wangler M . Inborn Errors of Metabolism Involving Complex Molecules: Lysosomal and Peroxisomal Storage Diseases. Pediatr Clin North Am. 2018; 65(2):353-373. DOI: 10.1016/j.pcl.2017.11.011. View

Wang J, Bhalla A, Ullman J, Fang M, Ravi R, Arguello A . High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II. Int J Mol Sci. 2020; 21(15). PMC: 7432392. DOI: 10.3390/ijms21155449. View

Breiden B, Sandhoff K . Mechanism of Secondary Ganglioside and Lipid Accumulation in Lysosomal Disease. Int J Mol Sci. 2020; 21(7). PMC: 7178057. DOI: 10.3390/ijms21072566. View

Campos D, Monaga M . Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms. Metab Brain Dis. 2012; 27(2):121-9. DOI: 10.1007/s11011-012-9302-1. View

Conroy M, Andrews R, Andrews S, Cockayne L, Dennis E, Fahy E . LIPID MAPS: update to databases and tools for the lipidomics community. Nucleic Acids Res. 2023; 52(D1):D1677-D1682. PMC: 10767878. DOI: 10.1093/nar/gkad896. View

Da Silva K, van de Lavoir M, Robeyns R, Iturrospe E, Verheggen L, Covaci A . Guidelines and considerations for building multidimensional libraries for untargeted MS-based metabolomics. Metabolomics. 2022; 19(1):4. DOI: 10.1007/s11306-022-01965-w. View

10.

De Pasquale V, Caterino M, Costanzo M, Fedele R, Ruoppolo M, Pavone L . Targeted Metabolomic Analysis of a Mucopolysaccharidosis IIIB Mouse Model Reveals an Imbalance of Branched-Chain Amino Acid and Fatty Acid Metabolism. Int J Mol Sci. 2020; 21(12). PMC: 7352355. DOI: 10.3390/ijms21124211. View

11.

Dufresne M, Guneysu D, Patterson N, Marcinkiewicz M, Regina A, Demeule M . Multimodal detection of GM2 and GM3 lipid species in the brain of mucopolysaccharidosis type II mouse by serial imaging mass spectrometry and immunohistochemistry. Anal Bioanal Chem. 2016; 409(5):1425-1433. DOI: 10.1007/s00216-016-0076-x. View

12.

Haucke V, Paolo G . Lipids and lipid modifications in the regulation of membrane traffic. Curr Opin Cell Biol. 2007; 19(4):426-35. PMC: 2042035. DOI: 10.1016/j.ceb.2007.06.003. View

13.

Lamari F, Mochel F, Sedel F, Saudubray J . Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases. J Inherit Metab Dis. 2012; 36(3):411-25. DOI: 10.1007/s10545-012-9509-7. View

14.

Mari M, Fernandez-Checa J . Sphingolipid signalling and liver diseases. Liver Int. 2007; 27(4):440-50. DOI: 10.1111/j.1478-3231.2007.01475.x. View

15.

Menkovic I, Lavoie P, Boutin M, Auray-Blais C . Distribution of heparan sulfate and dermatan sulfate in mucopolysaccharidosis type II mouse tissues pre- and post-enzyme-replacement therapy determined by UPLC-MS/MS. Bioanalysis. 2019; 11(8):727-740. DOI: 10.4155/bio-2018-0306. View

16.

Mires S, Sommella E, Merciai F, Salviati E, Caponigro V, Basilicata M . Plasma metabolomic and lipidomic profiles accurately classify mothers of children with congenital heart disease: an observational study. Metabolomics. 2024; 20(4):70. PMC: 11219374. DOI: 10.1007/s11306-024-02129-8. View

17.

Pinheiro C, Ribeiro R, Roginski A, Brondani M, Zemniacak A, Hoffmann C . Disturbances in mitochondrial bioenergetics and control quality and unbalanced redox homeostasis in the liver of a mouse model of mucopolysaccharidosis type II. Mol Cell Biochem. 2024; 480(1):411-424. DOI: 10.1007/s11010-024-04952-y. View

18.

Roberts J, Stewart C, Kearney S . Management of the behavioural manifestations of Hunter syndrome. Br J Nurs. 2016; 25(1):22, 24, 26-30. DOI: 10.12968/bjon.2016.25.1.22. View

19.

Saville J, Fuller M . Sphingolipid dyshomeostasis in the brain of the mouse model of mucopolysaccharidosis type IIIA. Mol Genet Metab. 2019; 129(2):111-116. DOI: 10.1016/j.ymgme.2019.08.008. View

20.

Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V . Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications. Front Neurosci. 2020; 14:572965. PMC: 7574889. DOI: 10.3389/fnins.2020.572965. View